| 1 |
35352806 | Epigenetic downregulation of Socs2 contributes to mutant N-Ras-mediated hematopoietic dysregulation. | 2022 May 1 |
1 |
| 2 |
31123029 | High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. | 2020 |
3 |
| 3 |
31732720 | Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations. | 2020 Apr |
1 |
| 4 |
29461617 | JAK/STAT5 signaling pathway inhibitor ruxolitinib reduces airway inflammation of neutrophilic asthma in mice model. | 2018 Feb |
2 |
| 5 |
29778097 | Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions. | 2018 May 19 |
1 |
| 6 |
25645356 | Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. | 2015 Mar 12 |
1 |
| 7 |
24957147 | JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. | 2014 Aug 28 |
2 |